Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 46Lung Neoplasms 19Small Cell Lung Carcinoma 5Melanoma 5Neoplasm Metastasis 4Neoplasms 3Brain Neoplasms 3Thymus Neoplasms 2Pancreatic Neoplasms 2Locally Advanced Non-small Cell Lung Cancer 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Thymic epithelial tumor 1Testicular Neoplasms 1Stomach Neoplasms 1

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced Non-small Cell Lung Cancer × Immunotherapy × Thoracic × Clear all
NCT06287320 2024-03-01

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown
200 enrolled
Thoracic

Locally Advanced Non-small Cell Lung Cancer

NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡